Italia markets closed

Dow Jones
38.829,28
+153,60(+0,40%)
Nasdaq
16.289,46
+133,13(+0,82%)
Nikkei 225
38.236,07
-38,03(-0,10%)
EUR/USD
1,0776
+0,0009(+0,09%)
Bitcoin EUR
58.747,64
-772,47(-1,30%)
CMC Crypto 200
1.362,48
+49,85(+3,80%)

NovoCure Limited (038.F)

Frankfurt - Frankfurt Prezzo differito. Valuta in EUR.

Aggiungi a watchlist

13,79

+0,64

(+4,91%)

In data: 09:24AM CEST. Mercato aperto.

Capitalizzazione	1,555B
Beta (5 anni mensile)	0,43
Rapporto PE (ttm)	N/D
EPS (ttm)	-1,89
Prossima data utili	02 mag 2024
Rendimento e dividendo (futuro)	N/D (N/D)
Data ex dividendo	N/D
Stima target 1A	177,14

Tutte

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in